| Literature DB >> 31006350 |
Raj Kumar Singh1, Kuldeep Dhama2, Sandip Chakraborty3, Ruchi Tiwari4, Senthilkumar Natesan5, Rekha Khandia6, Ashok Munjal6, Kranti Suresh Vora7, Shyma K Latheef2, Kumaragurubaran Karthik8, Yashpal Singh Malik9, Rajendra Singh2, Wanpen Chaicumpa10, Devendra T Mourya11.
Abstract
Nipah (Nee-pa) viral disease is a zoonotic infection caused by Nipah virus (NiV), a paramyxovirus belonging to the genus Henipavirus of the family Paramyxoviridae. It is a biosafety level-4 pathogen, which is transmitted by specific types of fruit bats, mainly Pteropus spp. which are natural reservoir host. The disease was reported for the first time from the Kampung Sungai Nipah village of Malaysia in 1998. Human-to-human transmission also occurs. Outbreaks have been reported also from other countries in South and Southeast Asia. Phylogenetic analysis affirmed the circulation of two major clades of NiV as based on currently available complete N and G gene sequences. NiV isolates from Malaysia and Cambodia clustered together in NiV-MY clade, whereas isolates from Bangladesh and India clusterered within NiV-BD clade. NiV isolates from Thailand harboured mixed population of sequences. In humans, the virus is responsible for causing rapidly progressing severe illness which might be characterized by severe respiratory illness and/or deadly encephalitis. In pigs below six months of age, respiratory illness along with nervous symptoms may develop. Different types of enzyme-linked immunosorbent assays along with molecular methods based on polymerase chain reaction have been developed for diagnostic purposes. Due to the expensive nature of the antibody drugs, identification of broad-spectrum antivirals is essential along with focusing on small interfering RNAs (siRNAs). High pathogenicity of NiV in humans, and lack of vaccines or therapeutics to counter this disease have attracted attention of researchers worldwide for developing effective NiV vaccine and treatment regimens.Entities:
Keywords: Nipah virus (NiV); bats; control; diagnosis; encephalitis; epidemiology; pathology; prevention; therapeutics; vaccines; zoonosis
Mesh:
Substances:
Year: 2019 PMID: 31006350 PMCID: PMC6830995
Source DB: PubMed Journal: Vet Q ISSN: 0165-2176 Impact factor: 3.320
Figure 1.Structure of Nipah virus.
Figure 2.Transmission of the Nipah virus. 1. Fruit bats acts as natural reservoir of Nipah viruses. Fruit bats with NiV feeds on date palm sap. Virus can survive in solutions that are rich in sugar, viz., fruit pulp. 2. Virus transmitted to human through the consumption of date palm sap. 3. Fruit bats of Pteropus spp. which are NiV reservoirs visited such fruit trees and got opportunity to naturally spill the drop containing virus in the farm to contaminate the farm soil and fruits. 4. Contaminated fruits are consumed by pigs and other animals. Pigs act as intermediate as well as amplifying host. Combination of close surroundings of fruiting trees, fruits-like date palm, fruit bats, pigs and human altogether form the basis of emergence and spread of new deadly zoonotic virus infection like Nipah. 5. Pork meat infected with NiV are exported to other parts. 6. Consumption of infected pork can act as a source of infection to human. 7. Close contact with NiV affected human can lead to spread of NiV to other persons.
Figure 3.Phylogenetic analyses of sequences of Nipah Virus (NiV) strains from different countries (Bangladesh, Cambodia, India, Malaysia, and Thailand). (A) Phyloanalysis based on complete G gene (1809 bp) and (B) Phyloanalysis based on complete N gene (1599 bp). Tree created with maximum likelihood method with 1,000 bootstrap replicates. Scale bars indicate number of sequence changes corresponding to illustrated branch length. Major two NiV clades are mentioned in the side bar as BD (Bangladesh) and MY (Malaysia).
Figure 4.Pathogenesis of NiV. 1. NiV can be seen in the epithelial cells of the bronchiole in the initial stage of infection. 2. NiV antigen can be detected in bronchi and alveoli. 3. Inflammatory mediators are activated as a result of infection to the airway epithelium. 4. Virus is disseminated to the endothelial cells of the lungs in the later stage of the disease. 5, 6. Virus enter the blood stream followed by dissemination, either freely or in host leukocyte bound form, reach brain, spleen and kidneys. 7. Two pathways are involved in the process of viral entry into the central nervous system (CNS), via hematogenous route and anterogradely via olfactory nerve nerves. 8. The blood brain barrier (BBB) is disrupted and IL-1β along with tumor necrosis factor (TNF)-α are expressed due to infection of the CNS by the virus which ultimately leads to development of neurological signs. Red font shows the symptoms in human.
Different vaccine strategies available for Nipah virus (NiV).
| Vector | Antigen used | Dose for immunization | Animal model | Route of vaccination | Administration frequency | Challenge with virus titer | Route of challenge | References |
|---|---|---|---|---|---|---|---|---|
| Vesicular stomatitis virus (VSV) | rVSV expressing NiV G | 105 plaque forming units (PFU) | Hamsters | Intraperitoneal | Single | 6.8 × 104 TCID50 (1000 LD50) | Intraperitoneal | DeBuysscher et al. |
| rVSV-ZEBOV-GP-NiVG | 107 PFU | African Green monkey | intramuscular | Single | 105 TCID50 (Malaysian strain) | Intratracheal | Prescott et al. | |
| rVSV-ΔG-NiVB/G | 107 PFU | Ferrets | Intramuscular | Single | ∼5 × 105 PFU | Equally divided between intratracheal and intranasal routes | Mire et al. | |
| Replication-defective VSV | 106 infectious particles | Female Syrian golden hamsters | Intramuscular | Single | 105 TCID50 per hamster (>1000 times LD50- Malaysian strain) | Intraperitoneal | Lo et al. | |
| Canarypox virus (ALVAC) vaccine vector | vCP2199, carrying the NiV-G and vCP2208, carrying the NiV F | 108 PFU | Landrace female pigs | Intramuscular | Boosted 14 days postvaccination | 2.5 × 105 PFU | Intranasal challenge | Weingartl et al. |
| Adeno-associated virus (AAV) | NiV G | 2.1010/1.1010 genome particles | Balb/c male mice | Intra muscular or intra-dermal | One Booster | 104 PFU | Intraperitoneal | Ploquin et al. |
| 6.1011 genome particles | Golden hamsters | Intra muscular | ||||||
| Vaccinia virus | NiV G and NiV F | 107 PFU | BALB/c female mice | Subcutaneously | Boosted with the same dose | 1,000 PFU | Intraperitoneal | Guillaume et al. |
| Measles virus based-vectors (HL strain or Edmonston B strain) | NiV G | 1 × 105 TCID50 | African green monkeys | Subcutaneously | One booster | 1 × 106 TCID50 | Intraperitoneal | Yoneda et al. |
| 2 × 104 TCID50 | Hamsters | Intraperitoneal | 1 × 108 TCID50 | Intranasal | ||||
| Venezuelan equine encephalitis virus replicon particles | NiV G | 3.1 × 105 IU | C3H/He mice | Foot pad inoculation | Single | Serum neutralization assay with pNL4-3.luc.E-R-reporter-gene encoding retroviruses pseudo-typed with NiV F + NiV G glycoproteins | – | Defang et al. |
| Newcastle disease virus (NDV), LaSota strains | NiVG and NiVF | 108 EID50 | Mice | Intramuscular | Single | Serum neutralization assay with VSVDGnGFP-NiV G/F pseudo- typed virus | – | Kong et al. |
| 2 × 109 EID50 | Pig | Intramuscular | ||||||
| Nipah virus-like particles (NiV-VLPs) | NiV G, F and M adjuvanted with Alum (50 µg -Alhydrogel 2%); MPLA (15 µg) and CpG ODN (40 µg) | 30 µg VLP | Golden Syrian hamsters | Intramuscular | Three-dose vaccination schedule | ∼16,000 PFU | Intraperitoneal | Walpita et al. |
Figure 5.Vaccine platforms for NiV. 1. Recombinant measles virus (rMV) vaccine that expresses envelope glycoprotein of NiV has been found to be effective vaccine candidate. 2. A recombinant vaccine based on vesicular stomatitis virus (replication-competent) has been developed in recent years encoding a glycoprotein of NiV. 3. Nipah virus-like particles (NiV-VLPs) composed of three NiV proteins G, F and M derived from mammalian cells have been produced and validated as vaccine in BALB/c mice. 4. Immunoinformatic advances have been utilized for developing peptide-based NiV vaccine by prediction and modeling of T-cell epitopes of NiV antigenic proteins.